PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP
The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic-<i>co...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/4/500 |
| _version_ | 1797538645865922560 |
|---|---|
| author | Kaining Zhi Babatunde Raji Anantha R. Nookala Mohammad Moshahid Khan Xuyen H. Nguyen Swarna Sakshi Tayebeh Pourmotabbed Murali M. Yallapu Harry Kochat Erene Tadrous Shelby Pernell Santosh Kumar |
| author_facet | Kaining Zhi Babatunde Raji Anantha R. Nookala Mohammad Moshahid Khan Xuyen H. Nguyen Swarna Sakshi Tayebeh Pourmotabbed Murali M. Yallapu Harry Kochat Erene Tadrous Shelby Pernell Santosh Kumar |
| author_sort | Kaining Zhi |
| collection | DOAJ |
| description | The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic-<i>co</i>-glycolic acid) (PLGA) is a biocompatible polymer that is used in Food and Drug Administration (FDA)-approved pharmaceutical products and medical devices. PLGA nanoparticles (NPs) have been reported to improve drug penetration across the BBB both in vitro and in vivo. Poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and poloxamer (Pluronic) are widely used as excipients to further improve the stability and effectiveness of PLGA formulations. Peptides and other linkers can be attached on the surface of PLGA to provide targeting delivery. With the newly published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP) technologies, manufacturing PLGA NP-based drug products can be achieved with higher efficiency, larger quantity, and better quality. The translation from bench to bed is feasible with proper research, concurrent development, quality control, and regulatory assurance. |
| first_indexed | 2024-03-10T12:34:23Z |
| format | Article |
| id | doaj.art-fefb54888c9548eea808ab02599ef367 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T12:34:23Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-fefb54888c9548eea808ab02599ef3672023-11-21T14:25:02ZengMDPI AGPharmaceutics1999-49232021-04-0113450010.3390/pharmaceutics13040500PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMPKaining Zhi0Babatunde Raji1Anantha R. Nookala2Mohammad Moshahid Khan3Xuyen H. Nguyen4Swarna Sakshi5Tayebeh Pourmotabbed6Murali M. Yallapu7Harry Kochat8Erene Tadrous9Shelby Pernell10Santosh Kumar11Plough Center for Sterile Drug Delivery Solutions, University of Tennessee Health Science Center, 208 South Dudley Street, Memphis, TN 38163, USAPlough Center for Sterile Drug Delivery Solutions, University of Tennessee Health Science Center, 208 South Dudley Street, Memphis, TN 38163, USACovance Inc., Kinsman Blvd, Madison, WI 53704, USADepartment of Neurology, College of Medicine, University of Tennessee Health Science Center, 855 Monroe Avenue, Memphis, TN 38163, USADepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USADepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USADepartment of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, 858 Madison Avenue, Memphis, TN 38163, USADepartment of Immunology and Microbiology, University of Texas Rio Grande Valley, McAllen, TX 78504, USAPlough Center for Sterile Drug Delivery Solutions, University of Tennessee Health Science Center, 208 South Dudley Street, Memphis, TN 38163, USADepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USADepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USADepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USAThe blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic-<i>co</i>-glycolic acid) (PLGA) is a biocompatible polymer that is used in Food and Drug Administration (FDA)-approved pharmaceutical products and medical devices. PLGA nanoparticles (NPs) have been reported to improve drug penetration across the BBB both in vitro and in vivo. Poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and poloxamer (Pluronic) are widely used as excipients to further improve the stability and effectiveness of PLGA formulations. Peptides and other linkers can be attached on the surface of PLGA to provide targeting delivery. With the newly published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP) technologies, manufacturing PLGA NP-based drug products can be achieved with higher efficiency, larger quantity, and better quality. The translation from bench to bed is feasible with proper research, concurrent development, quality control, and regulatory assurance.https://www.mdpi.com/1999-4923/13/4/500poly(lactic-<i>co</i>-glycolic acid) (PLGA)blood–brain barrier (BBB)current Good Manufacturing Practice (cGMP)Food and Drug Administration (FDA)nanotechnology |
| spellingShingle | Kaining Zhi Babatunde Raji Anantha R. Nookala Mohammad Moshahid Khan Xuyen H. Nguyen Swarna Sakshi Tayebeh Pourmotabbed Murali M. Yallapu Harry Kochat Erene Tadrous Shelby Pernell Santosh Kumar PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP Pharmaceutics poly(lactic-<i>co</i>-glycolic acid) (PLGA) blood–brain barrier (BBB) current Good Manufacturing Practice (cGMP) Food and Drug Administration (FDA) nanotechnology |
| title | PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP |
| title_full | PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP |
| title_fullStr | PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP |
| title_full_unstemmed | PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP |
| title_short | PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP |
| title_sort | plga nanoparticle based formulations to cross the blood brain barrier for drug delivery from r d to cgmp |
| topic | poly(lactic-<i>co</i>-glycolic acid) (PLGA) blood–brain barrier (BBB) current Good Manufacturing Practice (cGMP) Food and Drug Administration (FDA) nanotechnology |
| url | https://www.mdpi.com/1999-4923/13/4/500 |
| work_keys_str_mv | AT kainingzhi plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT babatunderaji plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT anantharnookala plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT mohammadmoshahidkhan plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT xuyenhnguyen plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT swarnasakshi plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT tayebehpourmotabbed plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT muralimyallapu plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT harrykochat plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT erenetadrous plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT shelbypernell plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp AT santoshkumar plgananoparticlebasedformulationstocrossthebloodbrainbarrierfordrugdeliveryfromrdtocgmp |